News
Guselkumab (Tremfya, Janssen) is a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis.
Trastuzumab and hyaluronidase-oysk subcutaneous injection approved for certain patients with HER2-positive early and metastatic breast cancer.
Potential adverse effects from health interventions, such as a drug reaction or an effect of a procedure, were not fully reported in more than one-third of published health study reviews.
.jpg "Cablivi Gets FDA Approval for Rare Blood Clotting Disorder")
Caplacizumab-yhdp treats adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting autoimmune disorder.
Pemetrexed plus pembrolizumab is indicated for use along with platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
About the Specialty Pharmacy Times Industry Guide
The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees.
The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.
